```html

Rectal Carcinoma – Comprehensive Medical Guide

Overview

Rectal carcinoma (also called rectal cancer) is a malignant tumor that originates in the lining of the rectum—the final 6‑8 cm of the large intestine just above the anal canal. It belongs to the broader category of colorectal cancer, which together accounts for roughly one‑third of all gastrointestinal cancers worldwide.

Who it affects: The disease most often occurs in adults over age 50, but incidence is rising in younger adults (under 45) in many high‑income countries. Men are slightly more likely than women to develop rectal cancer (about 55% vs 45%).

Prevalence: According to the World Health Organization and the International Agency for Research on Cancer, there were ~1.9 million new cases of colorectal cancer in 2020, with ~30% located in the rectum. In the United States, the American Cancer Society estimates ~44,000 new rectal cancer cases and ~9,000 deaths in 2024, representing a 4%‑5% annual increase in early‑onset disease.

Symptoms

Rectal carcinoma may develop silently for months or years. When symptoms appear, they can vary based on tumor size, location, and whether the cancer has spread.

Common symptoms

• Changes in bowel habits – new constipation, diarrhea, or a feeling that the bowel does not empty completely.
• Rectal bleeding – bright red blood on toilet paper or dark, tarry stools (melena) indicating upper‑rectal or more proximal bleeding.
• Abdominal or pelvic pain – crampy or dull discomfort that may worsen after eating.
• Unexplained weight loss – loss of >10 lb (4.5 kg) without dieting.
• Fatigue – often secondary to anemia from chronic blood loss.
• Feeling of incomplete evacuation – urgency or tenesmus (persistent urge to defecate).
• Change in stool caliber – narrower (pencil‑thin) stools.

Less common but serious signs

• Unexplained fever or night sweats.
• Sudden obstruction causing severe abdominal bloating and vomiting.
• Fistula formation (abnormal connection) or perforation leading to severe abdominal pain.

Causes and Risk Factors

Rectal carcinoma results from the accumulation of genetic mutations that drive uncontrolled cell growth. While many cases arise without an identifiable cause, several well‑established risk factors increase likelihood.

Genetic and hereditary factors

• Familial adenomatous polyposis (FAP) – hundreds of polyps develop in the colon and rectum; near‑certain risk of cancer if untreated.
• Lynch syndrome (hereditary non‑polyposis colorectal cancer, HNPCC) – mismatch‑repair gene mutations raise lifetime colorectal cancer risk to 50‑80%.
• Family history of colorectal cancer in a first‑degree relative (especially diagnosed before age 60).

Environmental and lifestyle factors

• Diet – high consumption of red/processed meats, low fiber, and low fruit/vegetable intake.
• Obesity – body‑mass index (BMI) ≥ 30 kg/m² is linked to a 20‑30% higher risk.
• Physical inactivity – sedentary lifestyle increases risk.
• Smoking – long‑term tobacco use raises risk by ~30%.
• Heavy alcohol use – >2 drinks per day for men, >1 for women.
• Chronic inflammatory bowel disease (IBD) – ulcerative colitis involving the rectum or Crohn’s disease of the colon.

Other contributors

• Diabetes mellitus (type 2)
• Prior radiation therapy to the pelvic region
• Older age (risk roughly doubles each decade after 50)

Diagnosis

Early detection greatly improves outcomes. If a clinician suspects rectal carcinoma based on history or physical exam, a systematic work‑up is pursued.

Initial evaluation

• Digital rectal exam (DRE) – Allows the doctor to feel a palpable mass or ulcerated lesion.
• Stool-based tests – Fecal immunochemical test (FIT) or guaiac‑based fecal occult blood test (FOBT) can detect hidden blood.

Imaging and endoscopy

• Colonoscopy with biopsy – Gold standard. Direct visualization of the tumor and removal of tissue for pathology.
• Flexible sigmoidoscopy – May be used for distal lesions but does not examine the proximal colon.
• Endorectal ultrasound (ERUS) – Provides detailed layer‑by‑layer images to assess depth of invasion (T‑stage).
• Magnetic resonance imaging (MRI) of the pelvis – Preferred for staging rectal cancer; evaluates mesorectal fascia, lymph nodes, and potential circumferential resection margin involvement.
• Computed tomography (CT) scan – Chest, abdomen, and pelvis CT to detect distant metastases (e.g., liver, lungs).
• Positron emission tomography (PET)–CT – Helpful in selected cases to locate occult metastases.

Pathology and molecular testing

• Histologic grade (well, moderately, poorly differentiated).
• Presence of lymphovascular or perineural invasion.
• Microsatellite instability (MSI) or mismatch‑repair (MMR) status – guides immunotherapy decisions.
• KRAS, NRAS, BRAF mutations – inform targeted therapy in metastatic disease.

Treatment Options

Treatment is individualized based on tumor stage (0‑IV), location within the rectum, patient’s overall health, and preferences. Multidisciplinary care involving surgical oncology, medical oncology, radiation oncology, gastroenterology, and supportive services yields the best results.

Early‑stage (Stage I‑II) disease

• Surgery – The cornerstone. Options include:
  • Low anterior resection (LAR) – Removes tumor while preserving sphincter function.
  • Total mesorectal excision (TME) – Precise removal of rectum and surrounding mesorectal fat to reduce local recurrence.
  • Abdominoperineal resection (APR) – Required for very low tumors; results in permanent colostomy.
• Adjuvant chemoradiotherapy – For high‑risk Stage II (e.g., T3/T4, poorly differentiated) to lower recurrence risk.

Locally advanced (Stage III) disease

• Neoadjuvant (pre‑operative) therapy – Long‑course chemoradiation (45‑50 Gy over 5 weeks + 5‑fluorouracil or capecitabine) shrinks tumor and improves surgical margins.
• Surgery – Performed 6‑12 weeks after neoadjuvant therapy.
• Adjuvant chemotherapy – Usually 6 months of FOLFOX (5‑FU, leucovorin, oxaliplatin) or CAPEOX (capecitabine + oxaliplatin).

Metastatic (Stage IV) disease

• Systemic chemotherapy – Regimens such as FOLFOX, FOLFIRI, or CAPEOX, often combined with targeted agents (e.g., bevacizumab, cetuximab) based on molecular profile.
• Immunotherapy – Pembrolizumab or nivolumab for MSI‑high or dMMR tumors.
• Surgery or ablative therapy – For isolated liver metastases or pulmonary lesions, potentially curative.
• Palliative radiation – Controls bleeding, pain, or obstruction.

Lifestyle and supportive measures

• Nutrition counseling – high‑protein, low‑sugar diet to support healing.
• Physical activity – early ambulation post‑surgery reduces complications.
• Pelvic floor physiotherapy – helps with continence after low anastomosis.
• Psychosocial support – counseling, support groups, and survivorship programs.

Living with Rectal Carcinoma

Adjusting to a cancer diagnosis involves practical day‑to‑day changes. Below are evidence‑based tips to enhance quality of life.

Stoma care (if applicable)

• Learn proper pouching techniques; contact a stoma nurse for fitting.
• Watch for skin irritation and change the pouch regularly.
• Stay hydrated – a colostomy can increase fluid loss.

Managing bowel function

• Limit high‑fiber foods immediately after surgery; gradually reintroduce as tolerated.
• Keep a bowel diary to identify triggers for urgency or incontinence.
• Consider medications such as loperamide for frequent stools or stool softeners for constipation.

Nutrition

• Eat small, frequent meals; prioritize lean proteins, whole grains, and cooked vegetables.
• Avoid spicy, caffeinated, or gas‑producing foods if they worsen symptoms.
• Supplement with vitamin D and calcium if long‑term steroids are used.

Emotional well‑being

• Join cancer survivor networks (e.g., American Cancer Society, CancerCare).
• Practice stress‑reduction techniques – mindfulness, gentle yoga, or breathing exercises.
• If persistent anxiety or depression develops, seek counseling or psychiatric support.

Follow‑up schedule

• Every 3‑6 months for the first 2 years: physical exam, CEA (carcino‑embryonic antigen) blood test, and colonoscopy at 1 year post‑resection.
• Then every 6‑12 months up to 5 years, then annually.
• Imaging (CT or MRI) based on oncologist recommendation, especially if CEA rises.

Prevention

While not all cases are preventable, adopting healthy habits dramatically lowers risk.

• Screening – Colonoscopy every 10 years starting at age 45 (or earlier for high‑risk individuals). Flexible sigmoidoscopy every 5 years or FIT annually are alternatives.
• Dietary changes – Increase fiber (≥25 g/day), consume at least 5 servings of fruits/vegetables, limit processed meats to <50 g/week.
• Weight management – Maintain BMI 18.5‑24.9 kg/m².
• Physical activity – ≥150 minutes of moderate aerobic exercise weekly.
• Avoid tobacco – Quit smoking; seek nicotine‑replacement or counseling.
• Limit alcohol – ≤2 drinks/day for men, ≤1 for women.
• Vaccination – Hepatitis B vaccination reduces liver metastasis complications; consider HPV vaccine (though primarily cervical).

Complications

If left untreated or when advanced disease progresses, several serious complications may arise.

• Bowel obstruction – Tumor blockage causing severe abdominal pain, vomiting, and distention; may require emergency surgery.
• Perforation – Full‑thickness wall breach leading to peritonitis, sepsis, and urgent operative repair.
• Bleeding – Chronic or acute hemorrhage can cause anemia or hemodynamic instability.
• Metastatic spread – Liver (most common), lungs, peritoneum, and distant lymph nodes.
• Fistula formation – Abnormal connections between rectum and adjacent organs (e.g., bladder, vagina).
• Post‑operative complications – Anastomotic leak, wound infection, urinary or sexual dysfunction due to nerve injury.
• Psychosocial impact – Depression, anxiety, and body‑image issues, especially after permanent colostomy.

When to Seek Emergency Care

---

Sources: Mayo Clinic, American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, World Health Organization, NCCN Clinical Practice Guidelines in Oncology (Rectal Cancer), Cleveland Clinic.

```